Tpharm.info


Side effects were reported





Diflucan (Fluconazole) Drug Information Side Effects and - RxList

11/29/2014
12:26 | Author: Emma Coleman

Side effects were reported
Diflucan (Fluconazole) Drug Information Side Effects and - RxList

Most of the reported side effects were mild to moderate in severity. Rarely, angioedema and anaphylactic reaction have been reported in marketing experience.

Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Tofacitinib Triazolam Oral Contraceptives Pimozide Quinidine Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine.

Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4.

Other Senses: Taste perversion.

DIFLUCAN is generally well tolerated.

During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg), the celecoxib Cmax and AUC increased by 68% and 134%, respectively.

Comments (1)Read more



Fortaz (Ceftazidime) Drug Information Side Effects and - RxList

11/29/2014
02:12 | Author: Emma Coleman

Side effects were reported
Fortaz (Ceftazidime) Drug Information Side Effects and - RxList

Learn about drug side effects and interactions for the drug Fortaz (Ceftazidime). Local Effects, reported in fewer than 2% of patients, were phlebitis and.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Hyperbilirubinemia, jaundice. Renal impairment.

Rare cases of hemolytic anemia have been reported.

In addition to the adverse reactions listed above that have been observed in patients treated with ceftazidime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:

Prolonged prothrombin time, false-positive test for urinary glucose, pancytopenia.

Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g., cardiopulmonary arrest); urticaria ; pain at injection site.

Read the Fortaz (ceftazidime) Side Effects Center for a complete guide to possible side effects.

Report Problems to the Food and Drug Administration.

Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients).

In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with FORTAZ and were reported spontaneously.

Comments (2)Read more

Phentermine Side Effects in Detail

11/29/2014
04:18 | Author: David Perry

Side effects were reported
Phentermine Side Effects in Detail

Only seven complaints of CNS effects were reported at 20 weeks. Complaints reported by patients include sleep difficulties, nervousness, depression, fatigue.

WADA Class WADA Anti-Doping Classification.

Pregnancy Category X Not for use in pregnancy.

Cardiovascular adverse effects may be associated with phentermine. Palpitations, tachycardia, elevation of blood pressure, ischemic event have been reported. Primary pulmonary hypertension and valvular heart disease has been reported in patients taking phentermine in combination with fenfluramine or dexfenfluramine and in rare cases in patients who have taken phentermine alone. Analysis of available data suggests that fenfluramine and dexfenfluramine are the causal agents, and both drugs have been withdrawn from the market as of September 15, 1997.

It is possible that some side effects of phentermine may not have been reported.

Comments (3)Read more

Aggrenox Side Effects in Detail

11/29/2014
06:44 | Author: Lauren Ross

Side effects were reported
Aggrenox Side Effects in Detail

Gastrointestinal (GI) symptoms were the most frequently reported side effects noted during clinical trials. The following adverse effects occurred at a rate equal to.

Gastrointestinal (GI) symptoms were the most frequently reported side effects noted during clinical trials. The following adverse effects occurred at a rate equal to or greater than 1% in patients receiving aspirin-dipyridamole and more frequently than in the placebo group (treatment vs. placebo, respectively): dyspepsia 18.4% vs. 16.7%, abdominal pain 17.5% vs. 14.5%, nausea 16.0% vs. 14.1%, diarrhea 12.7% vs. 9.8%, vomiting 8.4% vs. 7.2%, rectal bleeding 1.6% vs. 0.8%, melena 1.9% vs. 0.8%, hemorrhoids 1.0% vs.

Comments (4)Read more

CDC - Summary of HPV Adverse Event Reports Published in JAMA

11/29/2014
02:10 | Author: David Perry

Side effects were reported
CDC - Summary of HPV Adverse Event Reports Published in JAMA

There were a total of 12,424 reports to VAERS of adverse events reports to show that a vaccine may be associated with a possible side effect.

The findings were generally not that different from what is seen in the safety reviews of other vaccines recommended for a similar age group, 9 to 26 years old (meningitis and Tdap). Based on the review of available information by FDA and CDC, the HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks. Top of Page Top of Page Top of Page.

The study looked for patterns in all adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) from when HPV vaccine was first licensed in June 2006 through December 31, 2008. This is the first nationwide published HPV postlicensure study that includes clinical review of medical records associated with reports to VAERS.

How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?

A CDC-FDA report analyzing adverse events following human papillomavirus (HPV) vaccine administration from June 2006 through December 2008 is now published in the Journal of the American Medical Association (JAMA) August 19, 2009 issue, “ Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. ”

To receive updates about this page, enter your address:

Comments (0)